Share-based Payment Arrangement, Expense of BridgeBio Pharma, Inc. from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BridgeBio Pharma, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • BridgeBio Pharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $35,264,000, a 30% increase year-over-year.
  • BridgeBio Pharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $138,427,000, a 21% increase year-over-year.
  • BridgeBio Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $113,866,000, a 1% decline from 2023.
  • BridgeBio Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $115,016,000, a 23% increase from 2022.
  • BridgeBio Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $93,828,000, a 11% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

BridgeBio Pharma, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $138,427,000 $35,264,000 +$8,133,000 +30% 01 Jul 2025 30 Sep 2025 10-Q 29 Oct 2025 2025 Q3
Q2 2025 $130,294,000 $37,339,000 +$15,888,000 +74% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $114,406,000 $29,390,000 +$540,000 +1.9% 01 Jan 2025 31 Mar 2025 10-Q 29 Apr 2025 2025 Q1
Q4 2024 $113,866,000 $36,434,000 -$699,000 -1.9% 01 Oct 2024 31 Dec 2024 10-K 20 Feb 2025 2024 FY
Q3 2024 $114,565,000 $27,131,000 -$99,000 -0.36% 01 Jul 2024 30 Sep 2024 10-Q 29 Oct 2025 2025 Q3
Q2 2024 $114,664,000 $21,451,000 -$5,725,000 -21% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $120,389,000 $28,850,000 +$5,373,000 +23% 01 Jan 2024 31 Mar 2024 10-Q 29 Apr 2025 2025 Q1
Q4 2023 $115,016,000 $37,133,000 +$14,549,000 +64% 01 Oct 2023 31 Dec 2023 10-K 20 Feb 2025 2024 FY
Q3 2023 $100,467,000 $27,230,000 +$8,572,000 +46% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $91,895,000 $27,176,000 -$1,129,000 -4% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $93,024,000 $23,477,000 -$804,000 -3.3% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $93,828,000 $22,584,000 +$71,000 +0.32% 01 Oct 2022 31 Dec 2022 10-K 20 Feb 2025 2024 FY
Q3 2022 $93,757,000 $18,658,000 +$2,528,000 +16% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $91,229,000 $28,305,000 -$3,730,000 -12% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $94,959,000 $24,281,000 -$10,615,000 -30% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $105,574,000 $22,513,000 +$10,367,000 +85% 01 Oct 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
Q3 2021 $95,207,000 $16,130,000 -$1,569,000 -8.9% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $96,776,000 $32,035,000 +$13,643,000 +74% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $83,133,000 $34,896,000 +$24,674,000 +241% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $58,459,000 $12,146,000 +$2,139,000 +21% 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
Q3 2020 $56,320,000 $17,699,000 +$11,922,000 +206% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $44,398,000 $18,392,000 +$15,034,000 +448% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $29,364,000 $10,222,000 +$7,990,000 +358% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $21,374,000 $10,007,000 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2022 2021 FY
Q3 2019 $5,777,000 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $3,358,000 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $2,232,000 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1

BridgeBio Pharma, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $113,866,000 -$1,150,000 -1% 01 Jan 2024 31 Dec 2024 10-K 20 Feb 2025 2024 FY
2023 $115,016,000 +$21,188,000 +23% 01 Jan 2023 31 Dec 2023 10-K 20 Feb 2025 2024 FY
2022 $93,828,000 -$11,746,000 -11% 01 Jan 2022 31 Dec 2022 10-K 20 Feb 2025 2024 FY
2021 $105,574,000 +$47,115,000 +81% 01 Jan 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
2020 $58,459,000 +$37,085,000 +174% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $21,374,000 +$15,307,000 +252% 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2022 2021 FY
2018 $6,067,000 +$4,226,000 +230% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $1,841,000 01 Jan 2017 31 Dec 2017 10-K 03 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.